ROR1 and breast cancer: It has been revealed that, in breast cancer, miR-30a suppresses EMT progress by targeting ZEB2 34, Slug 35, Snail 36, ITGB3 37, and ROR1 38, and inhibits CSC properties by targeting Nanog 39, and AVEN 40.